Literature DB >> 11171611

Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.

W Wang1, A Basinger, R A Neese, B Shane, S A Myong, M Christiansen, M K Hellerstein.   

Abstract

Our objective was to examine very low density lipoprotein-triglyceride (VLDL-TG) kinetics after chronic and acute administration of nicotinic acid (NA). Incorporation of [1,2,3,4-(13)C(4)]palmitate and [2-(13)C(1)]glycerol into VLDL-TG was measured in five healthy, normolipidemic women. Each subject was studied twice; the 4-day hospital stays were separated by 1 mo, during which time doses of NA were increased to 2 g/day (500 mg, 4 times/day). During posttreatment study, 500 mg of NA were administered acutely at 0800. Under baseline postabsorptive conditions, incorporation curves from (13)C-labeled free fatty acid (FFA) and (13)C-labeled glycerol were superimposable, and VLDL-TG kinetics were in agreement (t(1/2) = 1.4 +/- 0.3 and 1.3 +/- 0.3 h, and production rates = 27.2 +/- 6.1 and 28.5 +/- 5.3 g/day, respectively). In the postabsorptive state after chronic NA therapy, VLDL-TG concentrations and production rates were lower despite a trend toward elevated plasma FFA concentrations and fluxes. After the acute dose of NA, plasma FFA concentrations and flux fell dramatically, and there was a virtual halt to VLDL-TG production, which continued throughout the 6-h period after NA, despite a marked rebound overshoot in serum FFA concentrations and flux after hour 2. Plasma homocysteine concentrations increased 68% (P < 0.001) in the NA phase, consistent with chronic increased transmethylation demand. We conclude that 1) NA acutely and chronically decreases VLDL-TG production rate in normal women; 2) the acute effect on VLDL-TG production is associated with an initial suppression of lipolysis but persists for several hours after the antilipolytic action of NA has abated and is observed in the basal postabsorptive state, when lipolytic rates are not reduced; and 3) the effect of NA on VLDL-TG production, therefore, cannot be completely explained by its antilipolytic actions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171611     DOI: 10.1152/ajpendo.2001.280.3.E540

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  15 in total

1.  Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.

Authors:  Burak Salgin; Maria L Marcovecchio; Rachel M Williams; Sarah J Jackson; Leslie J Bluck; Sandy M Humphreys; Carlo L Acerini; David B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

2.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.

Authors:  Elisa Fabbrini; B Selma Mohammed; Kevin M Korenblat; Faidon Magkos; Jennifer McCrea; Bruce W Patterson; Samuel Klein
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

3.  Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid.

Authors:  Carlos Hernandez; Matthew Molusky; Yaqiang Li; Siming Li; Jiandie D Lin
Journal:  Cell Metab       Date:  2010-10-06       Impact factor: 27.287

4.  Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.

Authors:  Stefania Lamon-Fava; Margaret R Diffenderfer; P Hugh R Barrett; Aaron Buchsbaum; Mawuli Nyaku; Katalin V Horvath; Bela F Asztalos; Seiko Otokozawa; Masumi Ai; Nirupa R Matthan; Alice H Lichtenstein; Gregory G Dolnikowski; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

5.  Extended-release niacin acutely suppresses postprandial triglyceridemia.

Authors:  M Haris U Usman; Arman Qamar; Ramprasad Gadi; Scott Lilly; Harsh Goel; Jaison Hampson; Megan L Mucksavage; Grace A Nathanson; Daniel J Rader; Richard L Dunbar
Journal:  Am J Med       Date:  2012-07-25       Impact factor: 4.965

6.  Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.

Authors:  Mattijs M Heemskerk; Sjoerd A A van den Berg; Amanda C M Pronk; Jan-Bert van Klinken; Mariëtte R Boon; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk; Vanessa van Harmelen
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-01-28       Impact factor: 4.310

7.  Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo.

Authors:  Faidon Magkos; Bettina Mittendorfer
Journal:  Clin Lipidol       Date:  2009-04-01

Review 8.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

9.  Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.

Authors:  Susan Kühnast; Mieke C Louwe; Mattijs M Heemskerk; Elsbet J Pieterman; Jan B van Klinken; Sjoerd A A van den Berg; Johannes W A Smit; Louis M Havekes; Patrick C N Rensen; José W A van der Hoorn; Hans M G Princen; J Wouter Jukema
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

Review 10.  Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.

Authors:  Jutta Dierkes; Sabine Westphal; Claus Luley
Journal:  Drug Saf       Date:  2003       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.